新型哈尔碱衍生物的合成与体外抗肿瘤活性研究

doi:10.6023/cjoc202112015

有机化学 ›› 2022, Vol. 42 ›› Issue (6): 1863-1871.DOI: 10.6023/cjoc202112015 上一篇下一篇

研究简报

新型哈尔碱衍生物的合成与体外抗肿瘤活性研究

胡冬燕^a^,^b, 韩广田^b, 李喜安^b, 任华忠^b, 岳李荣^b, 郭力^a^,^*(), 封家福^b^,^*()

a 成都中医药大学药学院中药资源系统研究与开发利用国家重点实验室成都 611137
b 乐山职业技术学院四川乐山 614000

收稿日期:2021-12-07 修回日期:2022-02-12 发布日期:2022-02-25
通讯作者: 郭力, 封家福
基金资助:
四川省中医药管理局科技(2020JC0069); 乐山市科技计划(20SZD067); 乐山市科技计划(20NZD007); 乐山职业技术学院科研基金(KY2019015); 乐山职业技术学院科研基金(KY2019016)

Synthesis and Evaluation in vitro of Novel Harmine Derivatives as Anticancer Activity Agents

Dongyan Hu^a^,^b, Guangtian Han^b, Xi'an Li^b, Huazhong Ren^b, Lirong Yue^b, Li Guo^a(), Jiafu Feng^b()

a State Key Laboratory of Resources Systems Research and Development Utilization of Traditional Chinese Medicine, School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu 611137
b Leshan Vocational & Technical College, Leshan, Sichuan 614000

Received:2021-12-07 Revised:2022-02-12 Published:2022-02-25
Contact: Li Guo, Jiafu Feng
Supported by:
Sichuan Provincial Administration of Traditional Chinese Medicine Technology Plan(2020JC0069); Science and Technology Plan of Leshan(20SZD067); Science and Technology Plan of Leshan(20NZD007); Research Foundation of Leshan Vocational & Technical College(KY2019015); Research Foundation of Leshan Vocational & Technical College(KY2019016)

文章分享

1. 221863S.pdf(2458KB)

摘要/Abstract

以哈尔碱为原料, 经过N⁹-甲基化、溴代、Suzuki偶联、脱Boc保护和酰胺化等步骤, 合成了一系列新型的6-位取代的哈尔碱衍生物, 目标化合物的结构经¹H NMR、¹³C NMR和高分辨质谱(HRMS)确证. 采用3-(4,5-二甲基噻唑-2-基)-5-(3-羧基甲氧基苯基)-2-(4-磺基苯基)-2H-四唑(MTS)法测试了目标化合物对白血病细胞HL-60、肺癌细胞A549、肝癌细胞SMMC-7721、乳腺癌细胞MCF-7和结肠癌细胞SW-480的增殖抑制作用. 实验结果表明, 部分化合物具有较好的抗肿瘤活性, 其中最强效的为化合物3o, 对HL-60、A549和SMMC-7721细胞的半数抑制浓度IC₅₀值分别为0.27, 0.44和0.048 μmol/L, 其活性强于阳性对照顺铂, 抗肝癌细胞SMMC-7721的活性强于对照紫杉醇.

关键词: 哈尔碱, 衍生化, 抗癌活性

A series of novel 6-substituted harmine derivatives were synthesized from harmine in five steps: N⁹-methylation, bromination, Suzuki coupling, N-Boc deprotection, and amidation reaction. The structures of target compounds were confirmed by ¹H NMR, ¹³C NMR, and high-resolution mass spectra (HRMS). The in vitro antiproliferative activities were evaluated in a panel of cancer cell lines (HL-60, A549, SMMC-7721, MCF-7 and SW-480) via 3-(4,5-dimethylthiazol-2-yl)-5-(3- carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) assay. The results indicated that some compounds had good to excellent activities, and especially the most potent compound was 3o, whose IC₅₀ values were 0.27 (against HL-60), 0.44 (against A549) and 0.048 μmol/L (against SMMC-7721), better than positive control drugs cisplatin and taxol (against SMMC-7721).

Key words: harmine, derivatization, antitumor activity

引用此文

胡冬燕, 韩广田, 李喜安, 任华忠, 岳李荣, 郭力, 封家福. 新型哈尔碱衍生物的合成与体外抗肿瘤活性研究[J]. 有机化学, 2022, 42(6): 1863-1871.

Dongyan Hu, Guangtian Han, Xi'an Li, Huazhong Ren, Lirong Yue, Li Guo, Jiafu Feng. Synthesis and Evaluation in vitro of Novel Harmine Derivatives as Anticancer Activity Agents[J]. Chinese Journal of Organic Chemistry, 2022, 42(6): 1863-1871.

导出引用 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

分享此文

图/表 3

参考文献 17

[1]	Cortes, J.; Perez-Garcia, J. M.; Llombart-Cussac, A.; Curigliano, G.; El Saghir, N. S.; Cardoso, F.; Barrios, C. H.; Javier Roman, Sh. W. M.; Harbeck, N.; Eniu, A.; Kaufman, P. A.; Tabernero, J.; García-Estévez, L.; Frcp, P. S.; Arribas, J. CA-Cancer J. Clin. 2020, 70, 105. doi: 10.3322/caac.21597 pmid: 32068901
[2]	Ali, I.; Wani, W. A.; Saleem, K.; Haque, A. Anticancer Agents Med. Chem. 2013, 13, 296. doi: 10.2174/1871520611313020016
[3]	(a) Wiseman. M. P. Nutr. Soc. 2008, 67, 253. doi: 10.1017/S002966510800712X pmid: 22897855
	(b) Leite de Oliveira, R.; Deschoemaeker, S; Henze, A.-T.; Debackere, K.; Finisguerra, V.; Takeda, Y.; Roncal, C.; Dettori, D.; Tack, E.; Jönsson, Y. Cancer Cell 2012, 22, 263. doi: 10.1016/j.ccr.2012.06.028 pmid: 22897855
[4]	Edwankar, C. R.; Edwankar, R. V.; Namjoshi, O. A.; Rallapalli, S. K.; Yang, J.; Cook, J. M. Curr. Opin. Drug Discovery Dev. 2009, 12, 752.
[5]	Chen, Q.; Chao, R. H.; Chen, H. S.; Hou, X. R.; Yan, H. F.; Zhou, S. F.; Peng, W. L.; Xu, A. L. Int. J. Cancer. 2005, 114, 675. pmid: 15609303
[6]	Shankaraiah, N.; Siraj, K. P.; Nekkanti, S.; Srinivasulu, V.; Sharma, P.; Senwar, K. R.; Sathish, M.; Vishnuvardhan, M. V. P. S.; Ramakrishna, S.; Jadala, C.; Nagesh, N.; Kamal, A. Bioorg. Chem. 2015, 59, 130. doi: 10.1016/j.bioorg.2015.02.007 pmid: 25771335
[7]	Jenkins, P. R.; Wilson, J.; Emmerson, D.; Garcia, M. D.; Smith, M. R.; Gray, S. J.; Britton, R. G.; Mahale, S.; Chaudhuri, B. Bioorg. Med. Chem. 2008, 16, 7728. doi: 10.1016/j.bmc.2008.07.002
[8]	Han, X. M.; Zhang, J.; Guo, L.; Cao, R. H.; Li, Y. Z.; Li, N; Ma, Q.; Wu, J. L.; Wang, Y. C.; Si, S. Y. PLoS One 2012, 7, e46546. doi: 10.1371/journal.pone.0046546
[9]	Figueiredo, P. D.; Perdomo, R. T.; Garcez, F. R.; Matos, M. D. C.; Carvalho, J. E.; Garcez, W. S. Bioorg. Med. Chem. Lett. 2014, 24, 1358. doi: 10.1016/j.bmcl.2014.01.039 pmid: 24507920
[10]	Trujillo, J. I.; Meyers, M. J.; Anderson, D. R.; Hegde, S.; Mahoney, M. W.; Vernier, W. F.; Buchler, I. P.; Wu, K. K.; Yang, S.; Hartmann, S. J.; Reitz, D. B. Bioorg. Med. Chem. Lett. 2009, 19, 2365. doi: 10.1016/j.bmcl.2008.07.105
[11]	Xin, B. T.; Tang, W. F.; Wang, Y.; Lin, G. W.; Liu, H. C.; Jiao, Y.; Zhu, Y.; Yuan, H. L.; Chen, Y. D.; Lu, T. Bioorg. Med. Chem. Lett. 2012, 22, 4783. doi: 10.1016/j.bmcl.2012.05.053
[12]	Du, H. T.; Gu, H. L.; Li, N.; Wang, J. R. Med. Chem. Commun. 2016, 7, 636. doi: 10.1039/C5MD00581G
[13]	(a) Insaf, F.; Jalloul, B.; Mansour, Z.; Fatima, B. E. G.; Hichem, B. J. J. Enzyme Inhib. Med. Chem. 2015, 30, 371. doi: 10.3109/14756366.2014.940932
	(b) Insaf, F.; Mohamed, A. B.; Aymen, B. N.; Jean, P. S.; Hichem, B. J.; Jalloul, B. J. Enzyme Inhib. Med. Chem. 2016, 31, 23.
[14]	Shi, B. X.; Cao, R. H.; Fan, W. X.; Guo, L.; Ma, Q.; Chen, X. M.; Zhang, G. X.; Qiu, L. Q.; Song, H. C. Eur. J. Med. Chem. 2013, 60, 10. doi: 10.1016/j.ejmech.2012.11.033
[15]	Cao, R. H.; Fan, W. X.; Guo, L.; Ma, Q.; Zhang, G. X.; Li, J. R.; Chen, X. M.; Ren, Z. H.; Qiu, L. Q. Eur. J. Med. Chem. 2013, 60, 135. doi: 10.1016/j.ejmech.2012.11.045
[16]	Sun, Y.; Guo, L.; Fan, W. X.; Chen, W.; Zhang, J.; Dai, B. Chin. J. Org. Chem. 2021, 41, 400. (in Chinese) doi: 10.6023/cjoc202006026
	( 孙跃, 郭亮, 范文玺, 陈伟, 张洁, 代斌, 有机化学, 2021, 41, 400.) doi: 10.6023/cjoc202006026
[17]	Cao, R. H.; Chen, Q.; Hou, X. R.; Chen, H. S.; Guan, H. J.; Ma, Y.; Peng, W. L.; Xu, A. L. Bioorg. Med. Chem. 2004, 12, 4613. doi: 10.1016/j.bmc.2004.06.038

Compd.	R¹	IC₅₀/(μmol•L^–1)^a
Compd.	R¹	HL-60	A549	SMMC-7721	MCF-7	SW-480
Harmine	—	44.71	36.47	17.43	27.75	22.08
3a	Phenyl	5.56	13.58	6.54	8.73	9.02
3b	p-Trifluoromethylphenyl	9.72	10.11	6.60	10.39	10.34
3c	p-Acetylphenyl	7.60	8.15	6.49	7.41	7.85
3d	Pyridine-4-yl	27.89	11.66	8.13	18.48	9.51
3e	Pyridine-3-yl	33.00	8.58	6.71	36.71	8.70
3f	Pyrimidine-5-yl	21.87	7.96	6.44	12.42	5.22
3g	Furan-3-yl	6.55	2.68	6.98	0.35	3.23
3h	Furan-2-yl	25.68	8.33	3.22	7.29	5.70
3i	Thiophene-2-yl	22.14	8.46	4.12	7.00	8.00
3j	Thiophene-3-yl	24.16	10.37	5.89	11.31	9.66
3k	2-Acetyl-thiophene-5-yl	7.70	1.63	20.71	29.92	9.48
3l	1-Methyl-1H-pyrazole-4-yl	9.86	3.85	0.35	0.94	2.00
3m	1-Methyl-1H-pyrazole-5-yl	79.99	60.81	33.20	58.97	60.66
3n	1-Methyl-1H-pyrazole-3-yl	5.96	25.42	23.19	14.34^c	15.47
3o	Isoquinolin-4-yl	0.27	0.44	0.048	22.34	2.01
3p	Isoquinolin-8-yl	NT^d	NT	2.52	NT	NT
3q	Isoquinolin-5-yl	NT	NT	2.76	NT	NT
3r	Quinolin-8-yl	NT	NT	3.23	NT	NT
3s	Quinolin-5-yl	NT	NT	0.17	NT	NT
3t	Naphthalen-1-yl	NT	NT	0.75	NT	NT
4	p-Aminophenyl	>100	8.62	6.66	22.68	9.08
顺铂^b	—	2.18	9.81	5.34	24.45	12.65
紫杉醇^b	—	<0.008	<0.008	0.16	<0.008	<0.008

Compd.	R¹	IC₅₀/(μmol•L^–1)^a
Compd.	R¹	HL-60	A549	SMMC-7721	MCF-7	SW-480
Harmine	—	44.71	36.47	17.43	27.75	22.08
3a	Phenyl	5.56	13.58	6.54	8.73	9.02
3b	p-Trifluoromethylphenyl	9.72	10.11	6.60	10.39	10.34
3c	p-Acetylphenyl	7.60	8.15	6.49	7.41	7.85
3d	Pyridine-4-yl	27.89	11.66	8.13	18.48	9.51
3e	Pyridine-3-yl	33.00	8.58	6.71	36.71	8.70
3f	Pyrimidine-5-yl	21.87	7.96	6.44	12.42	5.22
3g	Furan-3-yl	6.55	2.68	6.98	0.35	3.23
3h	Furan-2-yl	25.68	8.33	3.22	7.29	5.70
3i	Thiophene-2-yl	22.14	8.46	4.12	7.00	8.00
3j	Thiophene-3-yl	24.16	10.37	5.89	11.31	9.66
3k	2-Acetyl-thiophene-5-yl	7.70	1.63	20.71	29.92	9.48
3l	1-Methyl-1H-pyrazole-4-yl	9.86	3.85	0.35	0.94	2.00
3m	1-Methyl-1H-pyrazole-5-yl	79.99	60.81	33.20	58.97	60.66
3n	1-Methyl-1H-pyrazole-3-yl	5.96	25.42	23.19	14.34^c	15.47
3o	Isoquinolin-4-yl	0.27	0.44	0.048	22.34	2.01
3p	Isoquinolin-8-yl	NT^d	NT	2.52	NT	NT
3q	Isoquinolin-5-yl	NT	NT	2.76	NT	NT
3r	Quinolin-8-yl	NT	NT	3.23	NT	NT
3s	Quinolin-5-yl	NT	NT	0.17	NT	NT
3t	Naphthalen-1-yl	NT	NT	0.75	NT	NT
4	p-Aminophenyl	>100	8.62	6.66	22.68	9.08
顺铂^b	—	2.18	9.81	5.34	24.45	12.65
紫杉醇^b	—	<0.008	<0.008	0.16	<0.008	<0.008

Compd.	R²	IC₅₀/(μmol•L^–1)^a
Compd.	R²	HL-60	A549	SMMC-7721	MCF-7	SW-480
Harmine	—	44.71	36.47	17.43	27.75	22.08
5a	Methyl	>100	74.49	28.11	>100	17.08
5b	Ethyl	35.33	12.09	12.97	22.84	10.07
5c	Propyl	37.38	42.36	33.20	>100	>100
5d	Cyclohexyl	6.89	2.45	1.65	7.31	3.86
5e	Tetrahydropyran-4-yl	>100	>100	>100	>100	>100
5f	Pyridine-3-yl	8.63	6.57	>100	9.90	65.76
5g	Thiophene-3-yl	1.60	1.60	3.31	9.66	1.95
5h	Tthiazole-4-yl	1.53	10.27	3.06	>100	>100
5i	1-Methyl-1H-imidazole-4-yl	1.61	2.10	1.67	>100	5.08
5j	3-(Difluoromethyl)-1-methyl-1H-pyrazole-4-yl	0.37	0.41	1.53	1.92	1.35
顺铂^b	—	2.18	9.81	5.34	24.45	12.65
紫杉醇^b	—	<0.008	<0.008	0.16	<0.008	<0.008

Compd.	R²	IC₅₀/(μmol•L^–1)^a
Compd.	R²	HL-60	A549	SMMC-7721	MCF-7	SW-480
Harmine	—	44.71	36.47	17.43	27.75	22.08
5a	Methyl	>100	74.49	28.11	>100	17.08
5b	Ethyl	35.33	12.09	12.97	22.84	10.07
5c	Propyl	37.38	42.36	33.20	>100	>100
5d	Cyclohexyl	6.89	2.45	1.65	7.31	3.86
5e	Tetrahydropyran-4-yl	>100	>100	>100	>100	>100
5f	Pyridine-3-yl	8.63	6.57	>100	9.90	65.76
5g	Thiophene-3-yl	1.60	1.60	3.31	9.66	1.95
5h	Tthiazole-4-yl	1.53	10.27	3.06	>100	>100
5i	1-Methyl-1H-imidazole-4-yl	1.61	2.10	1.67	>100	5.08
5j	3-(Difluoromethyl)-1-methyl-1H-pyrazole-4-yl	0.37	0.41	1.53	1.92	1.35
顺铂^b	—	2.18	9.81	5.34	24.45	12.65
紫杉醇^b	—	<0.008	<0.008	0.16	<0.008	<0.008

新型哈尔碱衍生物的合成与体外抗肿瘤活性研究

Synthesis and Evaluation in vitro of Novel Harmine Derivatives as Anticancer Activity Agents

RichHTML

PDF

补充材料

可视化

摘要/Abstract

引用此文

分享此文

图/表 3

参考文献 17

相关文章 15

编辑推荐

相关统计

本文评价

[1]	钟玉梅, 邹小颖, 卓小丫, 王逸涵, 申佳奕, 郑绿茵, 郭维. 4-氧代-2-亚胺基噻唑烷-5-亚基乙酸乙酯类化合物的设计、合成及抗癌活性[J]. 有机化学, 2023, 43(4): 1452-1461.
[2]	李莎, 孙雅涵, 蒙燕葵, 李筱芳, 张少伟. 去甲咔咯的合成及其衍生化反应的进展[J]. 有机化学, 2022, 42(8): 2390-2405.
[3]	李猛, 孙凯. 银催化三氟甲硫基化-环化-水解: 含F₃CS基喹啉酮合成[J]. 有机化学, 2022, 42(7): 2089-2097.
[4]	赵静, 金辄, 王润, 张新庚, 韩英妹, 胡春, 刘晓平, 张传明, 金丽萍. 2-[(吡啶-2-基甲基)硫基]-1H-苯并咪唑类化合物的设计、合成和抗癌活性研究[J]. 有机化学, 2022, 42(7): 2172-2183.
[5]	陈睿嘉, 周聪, 逄锡文, 刘佳君, 顾玉诚, 刘建文, 李忠. 以环丙烷限制构象的新型双酰胺的设计、合成、抗癌活性及计算分析[J]. 有机化学, 2022, 42(1): 277-292.
[6]	刘新, 许润梅, 王淋, 刘雅雪, 陈志豪, 秦巍, 田玉顺. 二氢噻吩并吡啶-查尔酮衍生物的合成及其体外抗肿瘤活性研究[J]. 有机化学, 2021, 41(9): 3550-3559.
[7]	祝洁, 杨文超, 张乘运, 吴磊. 近十年Dendralenes催化合成研究进展[J]. 有机化学, 2021, 41(3): 1081-1097.
[8]	力瓦衣丁·买合苏提, 於俊杰, 王琪, 曹建国, 黄国正. 次大风子素酰胺类衍生物的合成及抗癌活性评价[J]. 有机化学, 2020, 40(9): 2764-2771.
[9]	于福强, 关爱莹, 孙旭峰, 李慧超, 李小武. 苯基吡唑氧基丙酸衍生物的设计、合成及其对水稻纹枯病的杀菌活性[J]. 有机化学, 2019, 39(2): 397-405.
[10]	廖世莉, 张国改, 曹涵, 陈碧莹, 李卫民, 吴霞, 冯毅凡. 小檗碱与和厚朴酚及槲皮素缀合物的合成及其体外抗肝癌HepG2细胞活性评价[J]. 有机化学, 2018, 38(6): 1549-1555.
[11]	刘娟娟, 卢言菊, 王婧, 毕良武, 赵振东. 异海松酰(胺)基硫脲类衍生物的合成及其生物活性评价[J]. 有机化学, 2017, 37(3): 731-738.
[12]	穆赫塔尔·伊米尔艾山, 萨提瓦力迪·海力力, 麦麦提依明·马合木提. 含羧基或酯基的N-甲基异噁唑啉盐的合成及其对细胞分裂周期25B磷酸酯酶和蛋白酪氨酸磷酸酶1的体外抗癌活性[J]. 有机化学, 2017, 37(2): 496-502.
[13]	陈艳华, 侯熙彦, 支德福, 李常, 田甜, 孙竞阳, 赵龙铉, 赵春晖. 齐墩果酸和熊果酸衍生物的合成、表征及抗癌活性的研究[J]. 有机化学, 2016, 36(4): 795-802.
[14]	廖启华, 林森, 邓瑞红, 黄志强, 邓柯玉, 严兆华. 含硅二烃基锡(IV)的2-巯基苯并噻唑配合物的合成、结构及抗癌活性[J]. 有机化学, 2015, 35(9): 1923-1928.
[15]	魏梦雪, 徐建, 张和, 李学强. 新型青蒿砜-酯类衍生物的合成及其抗癌活性研究[J]. 有机化学, 2015, 35(5): 1097-1103.